Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions
Alpha Tau Medical Ltd. announced the completion of patient enrollment in its IMPACT multicenter pilot study evaluating Alpha DaRT® combined with first-line chemotherapy for unresectable pancreatic cancer. Enrollment was expanded from 12 to 48 patients due to strong demand. Data release is expected in early 2027 to inform a pivotal study. The study …